Global X MSCI Argentina ETF vs IDEXX Laboratories, Inc. — how do they compare? Global X MSCI Argentina ETF trades at $91.07, while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: Global X MSCI Argentina ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| ARGT | IDXX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $102.94 | $766.68 |
52-Week Low | $67.55 | $526.44 |
Market Cap | — | $46.22B |
Enterprise Value | — | $47.12B |
Signals from Pluang's Aura AI — not financial advice
ARGT, the Global X MSCI Argentina ETF, trades at $91.13, down 2.46% on the day, with a bearish technical signal from moving averages. Recent news highlights Argentina's economic reforms under the Milei administration as a potential catalyst. The ETF's valuation is noted as attractive relative to historical averages, though key financial ratios are not currently available in the provided data.
The outlook hinges on Argentina's continued economic stabilization. Upside potential exists if reforms sustain, but significant risks include political volatility and the ETF's heavy concentration in a few holdings like MercadoLibre, which could amplify losses if sentiment sours.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Trailing returns across standard periods
Latest headlines on both assets
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →